These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 16452556

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M, Feldman L, Bhattacharjee V, Harkins P, Kadam S, Lo C, Ravi M, Shringarpure DT, Mardekian J, Cassino C, Coté T.
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Orphan drugs--medications for patients with rare diseases].
    Thielke D, Thyssen JP, Hansen BJ.
    Ugeskr Laeger; 2006 Jun 05; 168(23):2236-8. PubMed ID: 16768975
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Law and research could add up to profitable niche drugs.
    Haefner B.
    Nature; 2007 Apr 19; 446(7138):856. PubMed ID: 17443162
    [No Abstract] [Full Text] [Related]

  • 28. Four Decades of Orphan Drugs and Priorities for the Future.
    Sinha MS, Stern AD, Rai AK.
    N Engl J Med; 2024 Jul 11; 391(2):100-102. PubMed ID: 38973724
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Ethical considerations in orphan drug approval and use.
    Kesselheim AS.
    Clin Pharmacol Ther; 2012 Aug 11; 92(2):153-5. PubMed ID: 22814660
    [Abstract] [Full Text] [Related]

  • 34. The needs of the few.
    Nature; 2010 Jul 08; 466(7303):160. PubMed ID: 20613796
    [No Abstract] [Full Text] [Related]

  • 35. Orphan drug development: an economically viable strategy for biopharma R&D.
    Meekings KN, Williams CS, Arrowsmith JE.
    Drug Discov Today; 2012 Jul 08; 17(13-14):660-4. PubMed ID: 22366309
    [Abstract] [Full Text] [Related]

  • 36. Orphan drug regulations. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2013 Jun 12; 78(113):35117-35. PubMed ID: 23767079
    [Abstract] [Full Text] [Related]

  • 37. First treatment for Hunter syndrome.
    FDA Consum; 2006 Jun 12; 40(6):5. PubMed ID: 17333554
    [No Abstract] [Full Text] [Related]

  • 38. [Orphan drugs: drugs for rare diseases].
    Schenk M.
    Dtsch Med Wochenschr; 2010 May 12; 135(18):p17. PubMed ID: 20455291
    [No Abstract] [Full Text] [Related]

  • 39. Adoption agents.
    Wapner J.
    Sci Am; 2010 Jun 12; 302(6):19-20. PubMed ID: 20521471
    [No Abstract] [Full Text] [Related]

  • 40. A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?
    Oo C, Rusch LM.
    J Clin Pharmacol; 2016 Mar 12; 56(3):257-9. PubMed ID: 26211513
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.